Patrícia Silva, PhD, director of science content —

Patrícia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. Patrícia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by Patrícia Silva

Corbus to Present Promising Data on Resunab as Systemic Sclerosis Treatment

Corbus Pharmaceuticals will present results showing that Resunab (JBT-101), the company’s cannabis-derived treatment for systemic sclerosis (SSc), can trigger specific molecular pathways which resolve inflammation and halt fibrosis. The data will be presented by Michael L. Whitfield, PhD, a molecular biology professor at Dartmouth and scientific founder of Celdara Medical,…

NavigAID SSc Assay Diagnoses Scleroderma Subgroups, Could Lead to New Therapies

Protagen has launched NavigAID SSc, a new disease stratification assay that, by measuring serum biomarkers, can define specific systemic sclerosis (SSc) patient subgroups, thereby facilitating differential diagnosis and supporting the development of personalized therapeutics in SSc. SSc is an autoimmune disorder in which the immune system attacks the body. The condition…

Cytori Publishes 2-Year Follow-up Data in Scleroderma Trial of Cell Therapy in Hand Dysfunction

Cytori Therapeutics recently published two-year clinical follow-up data of its SCLERADEC-I pilot trial showing that a single administration of the company’s Cytori Cell Therapy (ECCS-50) provided sustained clinical benefits for patients with hand dysfunction linked to scleroderma. The study, “Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into…

Study of Systemic Sclerosis and Neuropsychiatric Ailments Now Recruiting Patients in France

A new clinical trial assessing neuropsychiatric complications in patients with systemic sclerosis — like depression and cognitive problems — is starting in France and currently recruiting patients. Until recently, systemic sclerosis (often also referred to as scleroderma)  — a connective tissue disorder — was thought to spare the central nervous system…